Prime Capital Investment Advisors LLC Has $1.72 Million Position in AstraZeneca PLC (NASDAQ:AZN)

Prime Capital Investment Advisors LLC reduced its position in shares of AstraZeneca PLC (NASDAQ:AZN) by 8.6% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 22,088 shares of the company’s stock after selling 2,068 shares during the period. Prime Capital Investment Advisors LLC’s holdings in AstraZeneca were worth $1,721,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also added to or reduced their stakes in the company. McClarren Financial Advisors Inc. lifted its holdings in AstraZeneca by 320.8% during the 3rd quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company’s stock worth $25,000 after purchasing an additional 247 shares during the last quarter. GHP Investment Advisors Inc. acquired a new position in AstraZeneca in the 2nd quarter valued at $26,000. Capital Performance Advisors LLP acquired a new position in AstraZeneca in the 3rd quarter valued at $28,000. Pathway Financial Advisers LLC acquired a new position in AstraZeneca in the 1st quarter valued at $29,000. Finally, Hobbs Group Advisors LLC acquired a new position in AstraZeneca in the 2nd quarter valued at $35,000. 20.35% of the stock is owned by institutional investors and hedge funds.

AstraZeneca Trading Up 0.2 %

Shares of AZN opened at $65.29 on Thursday. AstraZeneca PLC has a 52-week low of $60.47 and a 52-week high of $87.68. The business’s fifty day moving average is $76.20 and its 200-day moving average is $78.47. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.89. The firm has a market cap of $202.44 billion, a price-to-earnings ratio of 31.24, a PEG ratio of 1.21 and a beta of 0.47.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. Erste Group Bank raised AstraZeneca from a “hold” rating to a “buy” rating in a report on Wednesday, September 11th. TD Cowen lifted their price objective on AstraZeneca from $90.00 to $95.00 and gave the company a “buy” rating in a report on Monday, August 12th. Finally, Deutsche Bank Aktiengesellschaft raised AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday, November 6th. Two equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $89.75.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.